Clinical Trials
Addex spin-out Neurosterix launches Phase 1 trial for novel schizophrenia drug
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
- By IPP Bureau
| January 09, 2026
Addex Therapeutics has announced that its spin-out company, Neurosterix, has launched a Phase 1 clinical trial for NTX-253, a promising new treatment for schizophrenia.
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor. The first-in-human study will assess the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
“The progression of NTX-253 into clinical studies represents an important milestone for both Neurosterix and Addex,” said Tim Dyer, Chief Executive Officer of Addex Therapeutics.
"Selective modulation of the M4 receptor through a PAM represents a novel therapeutic approach compared to traditional dopamine receptor antagonists and has the potential to provide patients suffering from schizophrenia with a differentiated efficacy and safety profile. We look forward to the progress of NTX-253 as it advances through clinical development.”
Neurosterix was spun out of Addex in April 2024, securing $65 million in Series A funding led by Perceptive Advisors, with Addex retaining a 20% stake in the company.
